drugset
drugset / Trial / NCT01541189

Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.

NCT01541189 ↗

Phase 4 Completed 200 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

To evaluate efficacy and safety of valsartan 160mg in Chinese hypertensive patients.

Timeline

Start
2012-02
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Valsartan Small molecule 160 mg —

Indications

hypertensive disorder